DR info

Clinical trials : 16 / Drugs : 27 - (DrugBank : 5) / Drug target genes : 5 - Drug target pathways : 28

Drugs and their primary sponsors and trial info

Aflibercept
   University Hospital, Bonn
      2015   Phase 2   NCT02537054   Germany;
CAS No.: 7758-16-9
   Tampere university hospital
      2018   Phase 2;Phase 3   EUCTR2018-001492-20-FI   Finland;
Disodium Pyrophosphate
   Tampere University Hospital
      2020   Phase 2   NCT04441671   -
Disodiumpyrophosphate
   Tampere University Hospital
      2019   Phase 2   EUCTR2019-002109-24-FI   Finland;
Eylea
   Medizinische Fakultät der Universität Bonn
      2015   Phase 2   EUCTR2014-005263-33-DE   Germany;
INZ-701
   Inozyme Pharma
      2021   Phase 1/Phase 2   NCT05030831   United Kingdom;United States;
   Inozyme Pharma, Inc.
      2021   Phase 1;Phase 2   EUCTR2020-004000-33-FR   France;
Intravitreal injection ranibizumab
   University Hospital, Bonn
      2007   Phase 2   NCT00510965   Germany;
Lansolprazole
   Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
      2018   Phase 2   EUCTR2016-004021-16-ES   Spain;
Lansoprazole
   Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
      2020   Phase 4   NCT04660461   Spain;
Lucentis
   Department of Ophthalmology, Bonn University
      2007   Phase 2   EUCTR2006-006231-49-DE   Germany;
   Novartis Pharma S.A.S
      2013   Phase 3   EUCTR2013-001421-55-FR   France;
RECOMBINANT HUMAN ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 FUSED TO THE FC FRAGMENT OF IGG1
   Inozyme Pharma, Inc.
      2021   Phase 1;Phase 2   EUCTR2020-004000-33-FR   France;
RFB002, rhuFab V2
   Department of Ophthalmology, Bonn University
      2007   Phase 2   EUCTR2006-006231-49-DE   Germany;
RFB002A
   Novartis Pharma S.A.S
      2013   Phase 3   EUCTR2013-001421-55-FR   France;
Ranibizumab
   Department of Ophthalmology, Bonn University
      2007   Phase 2   EUCTR2006-006231-49-DE   Germany;
Ranibizumab injection (0.5 mg)
   Manhattan Eye, Ear & Throat Hospital
      2007   Phase 1/Phase 2   NCT00470977   United States;
SODIUM ACID PYROPHOSPHATE SAPP ROR 28 FOOD GRADE
   Tampere university hospital
      2018   Phase 2;Phase 3   EUCTR2018-001492-20-FI   Finland;
Study comparator ETI
   Centre Hospitalier Universitaire de Nice
      2021   Phase 2   NCT04868578   France;
Study treatment PPI
   Centre Hospitalier Universitaire de Nice
      2021   Phase 2   NCT04868578   France;